Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study

被引：65
作者：
Mateos, Maria-Victoria [1 ,2 ]
Orlowski, Robert Z. [3 ]
Ocio, Enrique M. [4 ,5 ]
Rodriguez-Otero, Paula [6 ]
Reece, Donna [7 ]
Moreau, Philippe [8 ]
Munshi, Nikhil [9 ]
Avigan, David E. [10 ]
Siegel, David S. [11 ]
Ghori, Razi [12 ]
Farooqui, Mohammed Z. H. [12 ]
Marinello, Patricia [12 ]
San-Miguel, Jesus [6 ]
机构：
[1] Complejo Asistencial Univ Salamanca, IBSAL, Salamanca, Spain
[2] USAL, CSIC, IBMCC, Ctr Invest Canc, Salamanca, Spain
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Hosp Univ Marques Valdecilla IDIVAL, Santander, Spain
[5] Univ Cantabria, Santander, Spain
[6] Clin Univ Navarra, CIMA, IDISNA, CIBERONC, Pamplona, Spain
[7] Princess Margaret Canc Ctr, Toronto, ON, Canada
[8] Univ Hosp Hotel Dieu, Nantes, France
[9] Dana Farber Canc Inst, Boston, MA 02115 USA
[10] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA
[11] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
[12] Merck & Co Inc, Kenilworth, NJ USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2019年 / 186卷 / 05期
关键词：
pembrolizumab; relapsed; refractory; multiple myeloma; lenalidomide; dexamethasone; IMMUNOTHERAPY;
D O I：
10.1111/bjh.15946
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E117 / E121
页数：5
相关论文
共 9 条
  • [1] Ahamadi M, 2017, CPT-PHARMACOMET SYST, V6, P49, DOI 10.1002/psp4.12139
  • [2] [Anonymous], 2017, ASCO Post
  • [3] Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma
    Badros, Ashraf
    Hyjek, Elizabeth
    Ma, Ning
    Lesokhin, Alexander
    Dogan, Ahmet
    Rapoport, Aaron P.
    Kocoglu, Mehmet
    Lederer, Emily
    Philip, Sunita
    Milliron, Todd
    Dell, Cameron
    Goloubeva, Olga
    Singh, Zeba
    [J]. BLOOD, 2017, 130 (10) : 1189 - 1197
  • [4] International uniform response criteria for multiple myeloma
    Durie, B. G. M.
    Harousseau, J-L
    Miguel, J. S.
    Blade, J.
    Barlogie, B.
    Anderson, K.
    Gertz, M.
    Dimopoulos, M.
    Westin, J.
    Sonneveld, P.
    Ludwig, H.
    Gahrton, G.
    Beksac, M.
    Crowley, J.
    Belch, A.
    Boccadaro, M.
    Turesson, I.
    Joshua, D.
    Vesole, D.
    Kyle, R.
    Alexanian, R.
    Tricot, G.
    Attal, M.
    Merlini, G.
    Powles, R.
    Richardson, P.
    Shimizu, K.
    Tosi, P.
    Morgan, G.
    Rajkumar, S. V.
    [J]. LEUKEMIA, 2006, 20 (09) : 1467 - 1473
  • [5] Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma
    Goerguen, Guellue
    Samur, Mehmet K.
    Cowens, Kristen B.
    Paula, Steven
    Bianchi, Giada
    Anderson, Julie E.
    White, Randie E.
    Singh, Ahaana
    Ohguchi, Hiroto
    Suzuki, Rikio
    Kikuchi, Shohei
    Harada, Takeshi
    Hideshima, Teru
    Tai, Yu-Tzu
    Laubach, Jacob P.
    Raje, Noopur
    Magrangeas, Florence
    Minvielle, Stephane
    Avet-Loiseau, Herve
    Munshi, Nikhil C.
    Dorfman, David M.
    Richardson, Paul G.
    Anderson, Kenneth C.
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (20) : 4607 - 4618
  • [6] Immunotherapy Combinations in Multiple Myeloma - Known Unknowns
    Gormley, Nicole J.
    Pazdur, Richard
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (19) : 1791 - 1795
  • [7] Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
    Lesokhin, Alexander M.
    Ansell, Stephen M.
    Armand, Philippe
    Scott, Emma C.
    Halwani, Ahmad
    Gutierrez, Martin
    Millenson, Michael M.
    Cohen, Adam D.
    Schuster, Stephen J.
    Lebovic, Daniel
    Dhodapkar, Madhav
    Avigan, David
    Chapuy, Bjoern
    Ligon, Azra H.
    Freeman, Gordon J.
    Rodig, Scott J.
    Cattry, Deepika
    Zhu, Lili
    Grosso, Joseph F.
    Garelik, M. Brigid Bradley
    Shipp, Margaret A.
    Borrello, Ivan
    Timmerman, John
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (23) : 2698 - +
  • [8] New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma
    Neri, Paola
    Bahlis, Nizar J.
    Lonial, Sagar
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (24) : 5959 - 5965
  • [9] Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma
    Tamura, H.
    Ishibashi, M.
    Yamashita, T.
    Tanosaki, S.
    Okuyama, N.
    Kondo, A.
    Hyodo, H.
    Shinya, E.
    Takahashi, H.
    Dong, H.
    Tamada, K.
    Chen, L.
    Dan, K.
    Ogata, K.
    [J]. LEUKEMIA, 2013, 27 (02) : 464 - 472
1